Skip to main content

Table 3 NSABP FB-7: Pathologic complete response (pCR) (breast and nodes) by treatment arm and HR status

From: Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

Treatment arms,

n = 42 each arm

Total pCR

P-value for pCR T vs Other Arms in all patientsa

pCR HR+

P-value for pCR T vs Other Arms in HR+ b

pCR HR

P-value for pCR T vs Other Arms in HR− b

P-value HR+ vs HR

Arm 1 (T)

16/41 (39.0%)

NA

8/27 (29.6%)

NA

8/14 (57.1%)

NA

0.11

Arm 2 (N)

14/42 (33.3%)

0.63

8/29 (27.6%)

1

6/13 (46.2%)

0.71

0.30

Arm 3 (T plus N)

21/42 (50%)

0.22

7/23 (30.4%)

1

14/19 (73.7%)

0.46

0.01

All arms

51/126 (40%)

 

23/79 (29%)

 

28/46 (61%)

 

0.001

  1. Abbreviations: T, trastuzumab; N, neratinib
  2. aCMH test stratified for the time period the patients were randomized to the study (prior/after the addition of Arm 3)
  3. bFisher’s exact test